Allogeneic Hematopoietic Cell Transplantation clinical trials at UC Davis
2 research studies open to eligible people
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
open to eligible people ages 18-75
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
Sacramento, California and other locations
Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases
open to all eligible people
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Sacramento, California and other locations
Our lead scientists for Allogeneic Hematopoietic Cell Transplantation research studies include Mehrdad Abedi, MD.
Last updated: